AGTX 0.16 Agentix Corp.
Range: | 0.021-0.09 | Vol Avg: | 2558 | Last Div: | 0 | Changes: | 0 |
Beta: | -1.35 | Cap: | 0.00B | Currency: | USD | Exchange: | PNK |
Sector: | Healthcare | IPO: | Fri Aug 21 2015 | Empoloyees: | |
CUSIP: | 00848A103 | CIK: | 0001603345 | ISIN: | US00848A1034 | Country: | US |
CEO: | Martin Schroeder | Website: | https://www.agentixcorp.com |
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of therapeutics to treat metabolic diseases. Its product pipeline includes AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was incorporated in 2013 and is based in Dana Point, California.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.